Hosted by Pharma Two B (Private)
Thursday, January 27, 2022
The webinar will feature a presentation by Parkinson’s Disease (PD) Key Opinion Leaders Robert Hauser, MD, MBA and C. Warren Olanow, MD, along with Sheila Oren, MD, MBA Pharma Two B CEO, to discuss the recently announced positive results from the pivotal Phase III Study of P2B001 in early Parkinson’s disease. This will be followed by a company update.
P2B001, an investigational drug, is a novel, once daily capsule of
Dr. Hauser and Dr. Olanow will discuss the unmet medical need for early-stage PD and the and will present the efficacy and safety profile of P2B001.
A live question and answer session will follow.